Trial Profile
Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab: a Pilot Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jun 2018
Price :
$35
*
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- 10 May 2018 Status changed from active, no longer recruiting to completed.
- 02 Mar 2018 Planned End Date changed from 31 Mar 2018 to 26 Mar 2018.
- 02 Mar 2018 Planned primary completion date changed from 31 Mar 2018 to 26 Mar 2018.